503 percent potential on a straight stock play?

*Sponsored by Lifewater Media. Please see disclosures below.

Good morning, Boardroom!

Circling back to what I was mentioning in last night’s email…

The bedrock of any well-balanced portfolio is made up of established, profitable companies that are sure to be economic mainstays for years… decades…or, ideally, generations.

But here’s the trouble with these companies —

Everyday investors already know about them.

Their stock prices rise and fall with the broader markets… only rarely outpacing the major indexes.

In the end, their upside is limited.

That’s why I spend so much time tracking down smaller companies with the potential to deliver explosive windfalls.

Companies that are one news story…one R&D breakthrough…one strategic merger away from a break out.

These are the hidden gems that you won’t hear about from Jim Cramer (if you do…RUN 🏃) or on the front page of the Wall Street Journal.

One such company that I want to look at today is Immix BioPharma (IMMX).

Based out of Los Angeles, IMMX is churning out highly promising therapies targeting cancers and immune disorders…

And while the value in such treatments is obvious —

Here are the real reasons you should care:

Its stock price has been on a tear…

This stock has been flying… and I don’t expect it to slow down anytime soon.

From its 52-week low of $0.68 in November, IMMX gained 335% in less than 120 market days, reaching an intraday peak of $2.96 just a few days ago —

That’s nearly DOUBLE mid-April’s trading price.

Those numbers are incredible in themselves, but they’re staggering when you consider that during the same November–May period that IMMX was rocketing into the stratosphere…

The S&P gained a piddling 2.5%.

Put another way, IMMX’s gain outpaced the SPY ETF 134 times.

Let me put that into perspective for you:

With a $10,000 initial investment and the same timing, that’s the difference between a potential profit of $33,500 versus a mere $250.

Does that mean I think smart traders should liquidate their stakes in SPY or that the next few months will replicate the monster move we have been witnessing? Absolutely not.

Like I said, solid companies like those in the S&P 500 should be the foundation of a balanced portfolio.

I’m drawing this comparison primarily to show that with small companies like IMMX, outsized gains are possible for traders with the right risk tolerance.

For another comparison, consider that it took Google (GOOG) — which flew high during the Covid era — six years to make the same gain that IMMX made in six months.

We’re talking literally about the difference between years and months.

If that doesn’t have your attention…

Prominent Roth Capital analyst forecasts a $14.00 price target.

With all IMMX’s momentum in the past six months, the obvious question is whether it still has room to run.

According to Jonathan Aschoff, Ph.D., a Managing Director and Senior Research Analyst at Roth Capital Partners, the answer is not only “yes” but “heck yes.”

Dr. Aschoff gave IMMX a buy rating in mid-February with a price target of a whopping $14.00. At the time, IMMX was trading for $2.32, a few cents above its opening price on the day of this writing.

Meaning…

Dr. Aschoff sees a potential upside of 503% — and that’s without using options.

Dr. Aschoff is a seasoned analyst with several “Best on the Street” awards from the Wall Street Journal, and he’s been recognized by Forbes, Financial Times, StarMine, and TipRanks.

Beyond his widely-recognized financial prowess, Dr. Aschoff’s doctorate in micro- and molecular biology gives him an incredible perspective on the DNA of biopharma gems like IMMX —

Establishing him as one of the foremost authorities on the biopharma space…

One who smart investors shouldn’t ignore.

But even with glowing recommendations from decorated industry insiders, it’s always important to look at a company’s fundamentals… roadmap…

And, unsurprisingly, it looks like Immix is running full steam ahead:

IMMX’s robust pipeline is tapping multiple growing (and critical) markets

The company’s lead therapeutic, IMX-110, is in Phase 1b/2a clinical trials, with an additional combination clinical trial in progress.

Earlier this month, the company reported positive clinical trial data for IMX-110 in combination with BeiGene / Novartis anti-PD-1 antibody tislelizumab: 100% tumor shrinkage in a case of advanced metastatic colorectal cancer.

The trials are ongoing, but if this treatment bears out, this will be a monumental medical breakthrough.

We’re talking about an effective treatment for the second most common cause of cancer death in the US.

In 2023 alone, an estimated 153,020 people will be diagnosed with colorectal cancer… and nearly one-third as many people will die from it.

Meaning the work of companies like IMMX is the best chance of survival for more than 50,000 people a year.

Humanitarian implications aside, one has to consider the fact that further successful trials could put IMMX at the top of the colorectal cancer market —

A niche that IndustryArc is expecting to reach $31.2 billion by 2025… up from a valuation of just $26.3 billion in 2019.

IMMX subsidiary Nexcella is also on the move, announcing positive clinical data on April 26 for its NXC-201 therapeutic that targets multiple myeloma and AL amyloidosis.

The trial, which involved 58 patients, showed a 92% overall response rate in relapsed/refractory multiple myeloma patients and a 100% overall response in patients with AL amyloidosis.

For perspective, there are over 35,000 people diagnosed with multiple myeloma in the US each year, and the $13.9 billion multiple myeloma market in 2017 is expected to reach $28.7 billion by 2027 according to Wilcock, et al. in Nature Reviews.

Al amyloidosis is a relatively rare condition, but its market is expected to grow from $3.6 billion in 2017 to $6 billion by 2025 according to Grand View Research.

Lightning in a Bottle?

With its low float and a tiny $33 million market cap, IMMX is a hotbed of volatility…

Which is precisely what I look for when it comes to the home-run potential of a “nano-cap” stock.

But remember — that also increases the risk potential, which is why any readers interested in the company should review the key details here to ensure it fits their trading profiles before making a move.

But if the past six months’ roaring momentum and Dr. Aschoff’s $14.00 price target are anything to go by…

Immix Biopharma is definitely worthy of your consideration. You can click right here to find out more, and do your own research to see if this is the type of opportunity that makes sense to you.

I’m signing out for now, but in the meantime, happy trading!

To Your Success,

*please see disclosures below

Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions